
A fight over a ban on hemp in Texas is pitting Republicans against Republicans
A successful push by Lt. Gov. Dan Patrick earlier this year to have the Legislature ban hemp and hemp-derived THC (tetrahydrocannabinol, the psychoactive ingredient in hemp and marijuana) was temporarily thwarted by Gov. Greg Abbott's veto of Senate Bill 3 on June 23. But just this week, a special 30-day legislative session was called by the governor, with THC as a top agenda item. A new bill, Senate Bill 5, nearly identical to the vetoed bill, is on the docket for legislators to consider.
Texas, by dint of its size and stature among red states, can be seen as a bellwether for how Republican lawmakers are going to handle the hemp and marijuana markets. The state legalized hemp products in 2019, modeling it after the federal Agriculture Improvement Act of 2018, which kick-started the contemporary hemp industry and cultivation across the country.
But the Texas law concerned itself more with agriculture and regulating the growing of hemp, which led to some oversights in terms of consumer regulation, said Katharine Harris, a drug policy expert at Rice University's Baker Institute for Public Policy. Products made with THC derived from hemp became legal, even while THC derived from marijuana plants remained banned. That's led to rapid growth and a consistent push—including from the industry itself—for more regulations.
'Texas has the potential to be the second-largest cannabis market in the country,' said Lukas Gilkey, founder of Hometown Hero CBD, a prominent advocate for the industry who previously launched ongoing legal action against state regulators to prevent them from banning hemp-derived TCH products in 2021. 'You used to be sent to jail for having a joint, but the numbers for this industry are staggering for an industry that isn't even six years old.'
A sudden multibillion-dollar industry
In the six years the hemp industry has existed in Texas, it's been on a speedrun toward becoming a sizable sector of the economy, according to a March 2025 Whitney Economics analysis. The industry now generates $267 million in state tax revenue, employing 53,000 workers who receive $2.1 billion in wages. Hometown Hero's revenues expanded five times over during the first six months after the law was passed.
Recreational marijuana is not legal to sell in the state—although Texas does have a small medical marijuana program —but possession of small amounts is starting to be decriminalized in some cities. However, since hemp is legal, the hemp industry in Texas can conduct transactions that pot sellers cannot, such as take credit card payments and engage in interstate commerce.
The growth of hemp in the state has garnered quite a constituency of small-business owners, entrepreneurs, and recreational users, as well as a sizable community of military veterans who utilize hemp goods for medicinal purposes. Many farmers have made hemp a main crop and were outraged that the industry was on the verge of closure.
'Throw the lowlifes in jail if you want to stop the bad actors,' Ann Gauger, co-owner of Caprock Family Farms in Lubbock, told The Texas Tribune. 'But don't take out the American farmers. Don't take out the ag producers.'
A battle for what Texas means
The battle over hemp in Texas can be cast as a battle about the personality of the frontier state itself: a no-nonsense, freedom-loving, self-made sense of pride in building a business with your bare hands versus a well-earned reputation as a right-wing policy incubator with deeply religious leaders.
There have been other attempts to regulate and reform hemp laws during other legislative sessions. (Texas has biannual sessions that last six months every other year.) But over the course of the last few years, the industry has grown substantially, to the point where it's quite visible, Harris said.
That has simply made some of the regulatory issues more obvious. For instance, manufacturing smokable hemp products was outlawed, but the sale of such items wasn't prohibited. The state's regulations also lacked more concrete restrictions around potency and age limits, and had few restrictions on where items could be sold: A retail license cost just $155 per location.
'One of the issues that we have right now is that there are a lot of unsafe products on the market because we don't have the oversight necessary,' Harris said. 'That's one of the things that they really need to fix.'
George Medici, a spokesperson for the Texas Hemp Business Council, said the industry itself has been advocating for new regulations—childproof packaging, age limits, setbacks to keep sales away from schools—so far, to no avail. Advocates have been busy lobbying in Austin during the special session, and they feel somewhat positive about the future.
'I think we're optimistic; it's kind of hard to tell,' Medici said. 'Polling suggests, and always has, that people want these products on the market, and want them regulated. The momentum is positive. What that'll look like making the sausage, I don't know.'
There are also efforts to push production of more industrial hemp, according to state Agriculture Commissioner Sid Miller, but that's just getting started. Miller believes that regardless of what happens with the regulation of products with THC, Texas will be a national leader in the hemp industry.
The potential for a full ban
It's also clear that the clash around hemp will continue. During a press conference about the issue, Lt. Gov. Patrick suggested that hemp producers might be part of a 'terrorist money-laundering scheme' and asked if the state really wanted everybody to get high.
Patrick and his allies in the Texas Legislature feel that hemp products have become too common, are too hard to police, and should be banned instead of regulated.
Rice University's Harris believes the current special session will likely deal with additional regulations around prohibiting access to minors and addressing additional regulations for the industry. She argues that any kind of ban would just push buyers to the illicit market, which would end up being more dangerous. Hometown Hero's Gilkey believes Senate Bill 5 will pass in the Senate but says that even if it does end up getting signed by the governor in the special session, he 'has a team of lawyers ready to sue them into oblivion.'
In the long term, the Texas hemp industry will have to adapt to a changing landscape and likely face a little more regulation, akin to what's already seen in many of the legal marijuana states, Harris said. She'd like to see an effort toward self-regulation and legislation that encourages better behavior within the industry, as far as guaranteeing the safety profiles of their products (as do many in the industry).
'The problem is that there's an industry and a market for these products that exists, so it becomes a lot harder to make it all go away,' she said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
XAI Madison Equity Premium Income Fund Declares its Monthly Distribution of $0.060 per Share
CHICAGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- XAI Madison Equity Premium Income Fund (the 'Fund'), has declared its regular monthly distribution of $0.060 per share on the Fund's common shares (NYSE: MCN) payable on September 2, 2025. The amount represents no change from the previous month's distribution amount. As mentioned in previous distribution declarations, the Fund has changed its distribution frequency from quarterly to monthly, which went into effect with the April 1, 2025 declaration. XA Investments believes this change enables investors to better manage their cash flow needs. Ex-Dividend Date August 15, 2025 Record Date August 15, 2025 Payable Date September 2, 2025 Amount $0.060 per share Change from Previous Month No Change The following dates apply to the declaration: Common share distributions may be paid from net investment income (regular interest and dividends), capital gains and/or a return of capital. The specific tax characteristics of the distributions will be reported to the Fund's common shareholders on Form 1099 after the end of the 2025 calendar year. Shareholders should not assume that the source of a distribution from the Fund is net income or profit. For further information regarding the Fund's distributions, please visit . The Fund's net investment income and capital gain can vary significantly over time; however, the Fund seeks to maintain more stable common share quarterly distributions over time. The Fund's final taxable income for the current fiscal year will not be known until the Fund's tax returns are filed. As a registered investment company, the Fund is subject to a 4% excise tax that is imposed if the Fund does not distribute to common shareholders by the end of any calendar year at least the sum of (i) 98% of its ordinary income (not taking into account any capital gain or loss) for the calendar year and (ii) 98.2% of its capital gain in excess of its capital loss (adjusted for certain ordinary losses) for a one-year period generally ending on December 31 of the calendar year (unless an election is made to use the Fund's fiscal year). In certain circumstances, the Fund may elect to retain income or capital gain to the extent that the Board of Trustees, in consultation with Fund management, determines it to be in the interest of shareholders to do so. The common share distributions paid by the Fund for any particular period may be more than the amount of net investment income from that period. As a result, all or a portion of a distribution may be a return of capital, which is in effect a partial return of the amount a common shareholder invested in the Fund, up to the amount of the common shareholder's tax basis in their common shares, which would reduce such tax basis. Although a return of capital may not be taxable, it will generally increase the common shareholder's potential gain, or reduce the common shareholder's potential loss, on any subsequent sale or other disposition of common shares. Future common share distributions will be made if and when declared by the Fund's Board of Trustees, after the evaluation of several factors, including the Fund's net investment income, financial performance and available cash. There can be no assurance that the amount or timing of common share distributions in the future will be equal or similar to that described herein or that the Board of Trustees will not decide to suspend or discontinue the payment of common share distributions in the future. The Fund's objective is to achieve a high level of current income and current capital gains, with long-term capital appreciation as a secondary objective. The Fund intends to pursue its objective by investing in a portfolio of common stocks and utilizing an option strategy, primarily by writing (selling) covered call options on a substantial portion of the common stocks in the portfolio in order to generate current income and gains from option writing premiums and, to a lesser extent, from dividends. Market action can impact dividend issuance as the Fund's total assets affect the Fund's future dividend prospects. The Fund provides additional information on its website at . About XA Investments XA Investments LLC ('XAI') serves as the Fund's investment adviser. XAI is a Chicago-based firm founded by XMS Capital Partners in 2016. XAI serves as the investment adviser for two listed closed-end funds and an interval closed-end fund. The listed closed-end funds, the XAI Octagon Floating Rate & Alternative Income Trust and XAI Madison Equity Premium Income Fund both trade on the New York Stock Exchange and the interval fund, Octagon XAI CLO Income Fund is available via direct subscription and through select broker/dealers and wealth management platforms. In addition to investment advisory services, the firm also provides investment fund structuring and consulting services focused on registered closed-end funds to meet institutional client needs. XAI offers custom product build and consulting services, including development and market research, sales, marketing, and fund management. XAI believes that the investing public can benefit from new vehicles to access a broad range of alternative investment strategies and managers. XAI provides individual investors with access to institutional-caliber alternative managers. For more information, please visit . About XMS Capital Partners XMS Capital Partners, LLC, established in 2006, is a global, independent, financial services firm providing M&A, corporate advisory and asset management services to clients. It has offices in Chicago, Boston and London. For more information, please visit . About Madison Investments Madison Investments is an independent investment management firm based in Madison, WI. The firm was founded in 1974, has approximately $28.3 billion in assets under management as of March 31, 2025, and is recognized as one of the nation's top investment firms. Madison offers domestic fixed income, U.S. and international equity, covered call, multi-asset, insurance and credit union investment management strategies. For more information, please visit .Madison and/or Madison Investments is the unifying tradename of Madison Investment Holdings, Inc., Madison Asset Management, LLC, and Madison Investment Advisors, LLC. Madison Funds are distributed by MFD Distributor, LLC. Madison is registered as an investment adviser with the U.S. Securities and Exchange Commission. MFD Distributor, LLC is registered with the U.S. Securities and Exchange Commission as a broker-dealer and is a member firm of the Financial Industry Regulatory Authority . XAI does not provide tax advice; please consult a professional tax advisor regarding your specific tax situation. Income may be subject to state and local taxes, as well as the federal alternative minimum tax. Investors should consider the investment objectives and policies, risk considerations, charges and expenses of the Fund carefully before investing. For more information on the Fund, please visit the Fund's webpage at . This press release shall not constitute an offer to sell or a solicitation to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer or solicitation or sale would be unlawful prior to registration or qualification under the laws of such state or jurisdiction. NOT FDIC INSURED NO BANK GUARANTEE MAY LOSE VALUE Media Contact:Kimberly Flynn, PresidentXA Investments LLCPhone: 888-903-3358Email: KFlynn@ in to access your portfolio
Yahoo
2 minutes ago
- Yahoo
US securities regulator announces AI task force
(Reuters) -The U.S. Securities and Exchange Commission said on Friday that it is creating an artificial intelligence task force to lead the agency's efforts to "enhance innovation and efficiency" in its operations. Valerie Szczepanik, who has been named the SEC's chief AI officer, will lead the task force, the regulator said in a statement. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 minutes ago
- Yahoo
Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its underwritten public offering of 43,700,000 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 5,700,000 additional shares of its common stock, at a public offering price of $3.30 per share. The underwriters did not receive any discounts or commissions with respect to an aggregate of 1,818,181 shares of common stock sold to the Cystic Fibrosis Foundation. All of the shares of common stock in the offering were sold by Prime Medicine. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $144.2 million. TD Cowen and BMO Capital Markets acted as joint book-running managers for the offering. The shares of common stock were offered by Prime Medicine pursuant to an effective shelf registration statement on Form S-3 that was previously filed with the U.S. Securities and Exchange Commission (SEC) on November 3, 2023 and declared effective by the SEC on November 13, 2023 (File No. 333-275321). The offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement relating to and describing the terms of the offering was filed with the SEC and is available on the SEC's website at Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, New York 10017, by telephone at (855) 495-9846, or by email at or BMO Capital Markets Corp., Attention: Equity Syndicate Department, 151 West 42nd Street, 32nd Floor, New York, New York 10036, by email at bmoprospectus@ This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About Prime Medicine Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Prime Editors are designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications. Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around our core areas of focus: liver, lung, and immunology and oncology. Across each core area, Prime Medicine is focused initially on a set of high value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path. Investor and Media ContactsGregory DearbornPrime Medicine857-209-0696gdearborn@ Hannah DeresiewiczPrecision